Safety and Efficacy Study of Investigational Pneumococcal Vaccine in Elderly Population

Phase 2 Completed 146 enrolled GlaxoSmithKline

RandomizedParallel-groupSingle-blindPrevention

Summary

As the licensed Pneumovax 23™ vaccine is not always satisfactory in elderly subjects, the safety and the immune response of the new investigational pneumococcal protein vaccine is evaluated in healthy elderly population.

Timeline

Start: 2004-01-20
Primary completion: 2005-03-30
Completion: 2005-03-30

Publications

Leroux-Roels I, Devaster JM, Leroux-Roels G, Verlant V, Henckaerts I, Moris P, Hermand P, Van Belle P, Poolman JT, Vandepapeliere P, Horsmans Y. Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: randomised, controlled trials. Vaccine. 2015 Jan 15;33(4):577-84. doi: 10.1016/j.vaccine.2013.10.052. Epub 2013 Oct 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GSK513026	Vaccine	—	Intramuscular
Comparator	Pneumovax 23	Vaccine	—	Intramuscular

Indications

No indication recorded.